Life Biosciences' ER‑100 Gene Therapy Administered to First Patient for Glaucoma
On June 9, 2024, the gene‑therapy ER‑100 was injected into the eye of the first human participant in Boston, Massachusetts. The treatment, developed by U.S. biotech Life Biosciences, uses a viral vector to deliver three of the four Yamanaka factors and is activated by doxycycline, aiming to partially reprogram retinal ganglion cells and reverse age‑related damage. The U.S. FDA approved the clinical study in January, and the trial plans to enroll up to 18 participants. The first cohort will treat 12 patients with open‑angle glaucoma, followed by a second cohort of up to six patients with non‑arteritic anterior ischemic optic neuropathy (NAION). The administration marks the world’s first human use of a rejuvenation‑focused gene therapy for an eye disease.
Entities: ER-100 · ER‑100 · Life Biosciences · Shinya Yamanaka · U.S. Food and Drug Administration · non‑arteritic anterior ischemic optic neuropathy (NAION) · open‑angle glaucoma · open‑angle glaucoma
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [● 12 SOURCES] ER‑100 delivers three of the four Yamanaka factors via a virus; gene expression is induced by doxycycline. (new)
- [● 12 SOURCES] ER‑100 aims to rejuvenate retinal ganglion cells via partial cellular reprogramming. (new)
- [● 12 SOURCES] The trial plans to enroll up to 18 participants. (new)
- [● 12 SOURCES] The U.S. FDA approved the ER‑100 clinical study in January. (new)
- [● 12 SOURCES] Life Biosciences is a U.S. biotech company developing the gene therapy ER‑100. (new)
- [● 12 SOURCES] The first cohort will include 12 patients with open‑angle glaucoma. (new)
- [● 12 SOURCES] The first human administration of ER‑100 was performed in June. (new)
- [● 12 SOURCES] A second cohort of up to six patients with non‑arteritic anterior ischemic optic neuropathy (NAION) will follow. (new)